Celularity Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Celularity Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CELU
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001752828
Board of directors
-
Dean C. Kehler · DirectorSince 2023
-
Diane L. Parks · DirectorSince 2023
-
Eschenbach Andrew C. Von · DirectorSince 2023
-
Geoffrey Ling M.D. · DirectorSince 2023
-
John Sculley · DirectorSince 2023
-
Kok Thay Lim · DirectorSince 2023
-
Marc Mazur · DirectorSince 2023
-
Peter Diamandis · DirectorSince 2023
-
Philip Alan Barach · DirectorSince 2026
- Since 2024
-
Robert J. Hariri · Director · Chief Executive OfficerSince 2023
-
Robin L. Smith · DirectorSince 2023
-
Vincent LeVien · DirectorSince 2025
Chief executives
Robert J. Hariri
· Chief Executive Officer
Dates unknown
Board connections
8 of this board's directors also sit on 14 other boards.
- via Richard J. Berman and Robert J. Hariri
- via Richard J. Berman and Robert J. Hariri
- via Dean C. Kehler
- via Eschenbach Andrew C. Von
- via Richard J. Berman
- via Diane L. Parks
- via Robin L. Smith
- via Marc Mazur
- via Dean C. Kehler
- via Richard J. Berman
- via Diane L. Parks
- via Marc Mazur
- via Eschenbach Andrew C. Von
- via John Sculley
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 13, 2026 | Brigido Stephen Officer (Pres., Functional Regeneration) | Option exercise | +821 | — | — |
| Apr 13, 2026 | Haines John R Officer (Senior Exec Vice President) | Option exercise | +1,641 | — | — |
| Apr 13, 2026 | Robert J. Hariri Director, Officer (Chief Executive Officer) | Option exercise | +3,281 | — | — |
| Apr 13, 2026 | Brigido Stephen Officer (Pres., Functional Regeneration) | Shares withheld for tax | −268 | $1.28 | $343 |
| Apr 13, 2026 | Haines John R Officer (Senior Exec Vice President) | Shares withheld for tax | −583 | $1.28 | $746 |
| Apr 13, 2026 | Robert J. Hariri Director, Officer (Chief Executive Officer) | Shares withheld for tax | −1,182 | $1.28 | $1,513 |
| Jan 12, 2026 | Geoffrey Ling M.D. Director | Grant or award | +19,231 | — | — |
| Jan 12, 2026 | Vincent LeVien Director | Grant or award | +28,847 | — | — |
| Jan 12, 2026 | Peter Diamandis Director | Grant or award | +20,385 | — | — |
| Jan 12, 2026 | Diane L. Parks Director | Grant or award | +30,000 | — | — |
| Dec 29, 2025 | Vincent LeVien Director | Grant or award | +125,000 | — | — |
| Dec 29, 2025 | Geoffrey Ling M.D. Director | Grant or award | +125,000 | — | — |
| Dec 29, 2025 | Diane L. Parks Director | Grant or award | +125,000 | — | — |
| Dec 29, 2025 | Peter Diamandis Director | Grant or award | +125,000 | — | — |
| Dec 19, 2025 | Diane L. Parks Director | Grant or award | +67,416 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.